Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Contract research organization PPD has confirmed that Takeda Pharmaceutical company's new drug application or NDA for alogliptin for the treatment of type 2 diabetes has been accepted for filing by the FDA.
Subscribe to our email newsletter
PPD partnered with Takeda to develop the compound. Under PPD’s agreement with Takeda, the FDA’s acceptance of the NDA filing triggers a $15 million milestone payment to PPD.
Fred Eshelman, PPD’s CEO, said: “We are pleased to partner with Takeda, one of the leading pharmaceutical companies in the area of diabetes. We are also delighted that this important regulatory milestone has been achieved as a result of close cooperation between Takeda and our company.”